DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Tipifarnib is an investigational drug.
There have been 79 clinical trials for Tipifarnib. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2004.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), Johnson & Johnson Pharmaceutical Research & Development, L.L.C., and Kura Oncology, Inc.
Recent Clinical Trials for Tipifarnib
|Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy||Kura Oncology, Inc.||Phase 2|
|Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS||Spanish Lung Cancer Group||Phase 2|
|Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia||Kura Oncology, Inc.||Phase 2|